UK Infectious Disease Therapeutics Market Analysis

UK Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the UK infectious disease therapeutics market will reach a value of $3.75 Bn from $3.12 Bn in 2022, growing at a CAGR of 2.4% during 2022-2030.

The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. Communicable diseases, often known as infectious diseases, are illnesses that can be passed from person to person directly or indirectly. Diseases such as measles or mumps can spread by coughing, sneezing or touching infected surfaces. Sexually transmitted diseases (STIs) and hepatitis are spread via bodily fluids like blood or sperm.

Several improvements in infectious disease therapies have occurred in recent years, including the creation of novel antibiotics and antiviral medications, as well as advances in immunotherapy and vaccine development. Immunotherapy is a new therapeutic approach that leverages the body's immune system to combat infectious diseases. The development of immunotherapies for diseases such as HIV and hepatitis C has received special attention in the UK. UK's government spends 12 % of its GDP on healthcare.

Market Dynamics

Market Growth Drivers Analysis

In response to the COVID-19 pandemic, the UK has made significant investments in the development and manufacturing of COVID-19 vaccines and therapies. Several medications, including remdesivir, dexamethasone, and tocilizumab, have been authorised for use in the UK to treat COVID-19. The Small Business Research Initiative (SBRI) and the Longitude Prize are two initiatives sponsored by the UK government to assist in the development of novel antibiotics. The UK has been involved in the development of various novel malaria treatments. Tafenoquine, a novel medicine that has been found to be effective against malaria and has recently been approved for use in the UK, is one example. Cutting-edge pharmaceuticals sectors in the UK give a push to the expansion. These aspects could boost UK infectious disease therapeutics market.

Market Restraints

The UK's low productivity and training deficit are not favourable to innovation. Developing new pharmaceuticals and treatments necessitates adhering to regulatory rules established by organisations such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. These factors may deter new entrants into the UK infectious disease therapeutics market.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK) - GSK is a major British pharmaceutical corporation. GSK has collaborated with other firms to develop and manufacture vaccines and therapies in response to the COVID-19 pandemic
• AstraZeneca - AstraZeneca is another major British pharmaceutical company that develops and manufactures infectious disease therapeutics. During the COVID-19 pandemic, AstraZeneca partnered with the University of Oxford to develop and manufacture a vaccine
• Oxford BioMedica - Oxford BioMedica is a British biopharmaceutical company that has been involved in the development of several vaccines and treatments for infectious diseases, including COVID-19
• Faron Pharmaceuticals - Faron Pharmaceuticals is a British biopharmaceutical company, that has a lead product, Traumakine, which is a potential treatment for COVID-19-induced acute respiratory distress syndrome
• Emergent BioSolutions - Emergent BioSolutions is a multinational biopharmaceutical company which develops and manufactures a range of infectious disease therapeutics, including vaccines and treatments for anthrax, smallpox, and botulism

Recent Notable Updates

December 2022: Following the European Commission's licence in November 2022, GSK has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults aged 18 and above in Great Britain.

Healthcare Policies and Reimbursement Scenarios

In the UK, the regulation of infectious disease therapeutics is primarily overseen by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is in charge of guaranteeing the safety, effectiveness, and high quality of all medicines and medical equipment, including those used to treat infectious diseases. In order to be licenced for use in the UK, infectious disease treatments must first go through a rigorous regulatory process that includes clinical studies and other testing to ensure their safety and efficacy. Following the approval of a product, the MHRA continues to monitor its safety and quality through post-marketing surveillance. Other UK regulatory bodies that may be involved in the regulation of infectious disease therapeutics, in addition to the MHRA, include the National Institute for Health and Care Excellence (NICE), which provides guidance on the use of new treatments within the NHS, and the Health and Safety Executive (HSE), which regulates the use of hazardous substances in the workplace.

In the UK, the National Health Service (NHS) manages the reimbursement of infectious disease medicines through a system known as the National Institute for Health and Care Excellence (NICE). NICE assesses new medications and therapies for efficacy, safety, and cost-effectiveness before recommending whether they should be paid for by the NHS.